-
Commonhold Explained: How New Leasehold Ban Changes Property Ownership in England and Wales
-
Factory Worker Dies in Rare Rectal Explosion Incident in Czechia
-
GIRLBAND! Headline Show at Rough Trade Marks National Breakthrough
-
Decoding UNFCCC Legal Language: The Hierarchy of Verbs in Climate Negotiations
-
Saudi PIF Retains Top Sovereign Wealth Fund Brand Title for Third Year
-
Banff Avenue Transforms into High-End Retail Hub Amid Local Business Concerns
-
Selena Gomez Launches Black Equality Fund to Support Racial Justice Organizations
-
Stemtech Corporation Partners with Fitness Icon Tony Little to Launch Stemtech Biosciences Digital Campaign
-
QNX Brings Physical AI and Next-Generation Software-Defined Vehicle Innovation to CES 2027
-
Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes
-
ATWEC Technologies, Inc. (OTCID: ATWT) Engages Michael Gillespie & Associates, PLLC to Audit Fiscal 2026 and 2025 Consolidated Financial Statements and Changes Fiscal Year End to October 31
-
Lumber's Union CBA Agent Launches in Sage Agent Marketplace to Help Simplify Union Payroll Compliance
-
Metano Emerges From Stealth to Unify AI Agent Security Across the Enterprise
-
The 2026 MDaudit Annual Benchmark Report Spotlights AI's Impact on Financial Risk as Payer Denials and Audits Continue an Upward Trajectory
-
MicroVision and Blue-Band to Support $3 Million Federally Funded Intelligent Transportation Initiative in Louisville, Kentucky
-
More Than Half of Teen AI Chatbot Users Use Them Daily, and 46% Say It Feels Like Talking to a Human, New Family Online Safety Institute Research Finds
-
Celtic Bank Selects Infinant to Scale Its Embedded Finance Programs
-
Go Green Global Technologies Corp. Appoints Dennis Beckert as Interim Chief Executive Officer
-
InstaLILY Launches Lily for Sales on Microsoft Dynamics 365, Where Sellers and AI Agents Work Together in Shared Rooms
-
Wave AI, the AI Note Taker for In-Person Meetings, Passes 5 Million Recorded Hours
-
Increasing Electrification Raises Grid Risk and Cost Pressure for Industrial Sites, ABI Research Finds
-
Jerash Holdings Partners with International Finance Corporation (IFC) to Pursue EDGE Gender Certification
-
Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled
-
Philadelphia Sexual Assault Lawyer David P. Thiruselvam Explains Who Can Be Named in a Civil Sexual Assault Claim
-
Long Island Capital Alliance to Host Technology Capital Forum
-
BlackBerry and Hazard Management Cayman Islands Renew Critical Alerting System for Emergencies and Public Safety
-
Medical Care Technologies Inc. (OTCID:MDCE) Pauses Dilution Through 2027 After Q3 Profitability Rebound and Infinite Auctions Private Sales Exceed $300,000 in Q4
-
Trustpoint Xposure Completes More Than 200 AI Visibility Audits Across Professional Services
-
Making the Most of a Long Weekend Without Leaving Town
-
Bob's Watches Founder Paul Altieri Unveils Private Collection of Vintage Rolex Watches in New Book, "NOT FOR SALE"
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 19
-
Hemogenyx Pharmaceuticals PLC - Chairman Receives Prestigious Award
-
American Critical Minerals Reports High Grade Potash Intersection of 6.55m Grading 38.51 wt.% KCl at its Green River Project, Utah
-
LASE to Premiere Quantum Bullet(TM) at Counter UAS Technology Conference in Washington, D.C.
-
First Canadian Graphite Reports 43.9% Graphitic Carbon Sample and Encouraging Coarse-Flake Characteristics at Zone 13 at Lac Guéret South
-
IRS Shuts Down FIRE Today: What Information Return Filers Need to Know Before the 2027 Filing Season
-
NoHo, Inc. Acquires Four Placer Gold Claims in Clark County, Nevada from Gold Stake Mining Inc.
-
Arrive AI Eliminates All Debt Through Preferred Equity Exchange
-
Gamma Resources Announces Expansion of Mesa Arc Uranium Project in New Mexico to 4,760 Acres, Completes Radon Flux Baseline Survey
-
Golden Minerals Completes Drilling Desierto, Argentina
-
Guanajuato Silver Reports Q3 Operating and Financial Results
-
Helio Corporation Engages CORE IR to Provide Investor Relations, Capital Markets Advisory and Media Relations Services
-
Greene Concepts Connects Consumer Needs with Manufacturing Strategy
-
Karbon-X (OTCQB:KARX) Enters California's Multi-Billion-Dollar Compliance Carbon Market Following CITSS Approval
-
Skilled Nursing Facilities Face 2027 Revenue Cycle Reckoning as Payer Burdens Reshape Admissions and Outsourcing
-
Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
-
multiQure Begins Manufacturing Phase of MQ-201 Gene Therapy for First Huntington's Disease Patients - U.S.-Based Andelyn Biosciences Selected as Manufacturing Partner
-
Nextech3D.ai Reports Fiscal Q2 2027 Financial Results: AI Event Technology Doubles Revenue
-
Who Is the Best MTF Top Surgeon?
-
Kolter Homes Introduces New Nancy Floorplan at Woodland Preserve in Parrish, Florida
Onco-Innovations Appoints Dr. Michael Lock to Scientific & Clinical Advisory Board
VANCOUVER, BC / ACCESS Newswire / September 22, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is pleased to announce the appointment of Dr. Michael Lock, Professor in the Department of Oncology and the Department of Medical Biophysics at the University of Western Ontario, to its Scientific and Clinical Advisory Board. Dr. Lock's expertise in clinical trial design, translational oncology, and multidisciplinary cancer care will support Onco in its development of novel therapies, including its PNKP inhibitor program.
Dr. Lock is a Professor at Western University in the Department of Oncology and the Department of Medical Biophysics. He is a staff radiation oncologist who trained at Princess Margaret Hospital, University of Toronto, McMaster University, and the University of Wisconsin. Over his career, he has held leadership roles as Chair of the Department of Radiation Oncology, Chief of Division of Radiation Oncology, Medical Director of the London Regional Cancer Program, and Southwest Regional Radiation Oncology Lead. His experience spans clinical operations, trial oversight, and strategic program development across multiple oncology subspecialties.
He has chaired and co-chaired several multidisciplinary site teams, including Breast Cancer, Genitourinary, and Hepatobiliary programs, ensuring integration of clinical research into patient care. Dr. Lock also served as Chair of the Radiation Oncology Provincial Advisory Committee, where he helped shape provincial priorities that established protocols and infrastructure that will serve patients for many years to come. He is an Associate Scientist with the Lawson Health Research Institute. His leadership in clinical trial methodology, coupled with his ability to align diverse research teams, will be highly relevant to Onco's translational and clinical pipeline.
In addition to his work in Canada, Dr. Lock has contributed to advancing cancer care globally through collaborations with the International Atomic Energy Agency (IAEA), the United Nations (UN), and the World Health Organization (WHO).[1] He has received multiple recognitions, including the Human Touch Award and the MAC Administrative Award, for his leadership and contributions to oncology.
"Dr. Lock's deep clinical trial expertise and proven leadership in integrating research with patient care make him an invaluable addition to our team. His perspective will be critical as Onco advances toward clinical development of our PNKP inhibitor program and other research initiatives, particularly in shaping trial strategy and execution," stated Thomas O'Shaughnessy, CEO of Onco-Innovations.
The Company also announces that its Board of Directors has approved a grant of 1,155,000 Restricted Share Units ("RSUs") to certain directors, officers, and consultants of the Company pursuant to the Company's equity incentive plan.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
[email protected]
Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Private Placement generally, and the anticipated closing date, use of proceeds and anticipated proceeds thereof, as well as to the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward- looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
[1] https://www.lhsc.on.ca/verspeeten-family-cancer-centre/michael-lock-md-ccfp-frcpc
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
P.A.Mendoza--AT